Get the Stockscreener App
1.82
3.12%
0.06
Actinium Pharmaceuticals Inc stock is traded at $1.82, with a volume of 115.95K.
It is up +3.12% in the last 24 hours and up +1.40% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.76
Open:
$1.76
24h Volume:
115.95K
Relative Volume:
0.15
Market Cap:
$56.08M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-1.00
EPS:
-1.82
Net Cash Flow:
$-47.49M
1W Performance:
-3.46%
1M Performance:
+1.40%
6M Performance:
-79.74%
1Y Performance:
-61.87%
1-Day Range:
$1.76
$1.85
1-Week Range:
$1.69
$1.89
52-Week Range:
$1.33
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge - MSN
Wall Street SWOT: Actinium stock rides wave of targeted therapy innovation - Investing.com
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) vs. Its Rivals Head to Head Comparison - Defense World
Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - Clinical Trials Arena
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Stocks of the Hour: Amplia Therapeutics, Wellard, Anax Metals - ShareCafe
Before Buying Anterix Inc (NASDAQ: ATEX) Stock, Read This First - Stocks Register
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc.ATNM - PR Newswire
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific - Clinical Trials Arena
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
ATNM: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Actinium Pharmaceuticals Inc (ATNM) requires closer examination - US Post News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - PR Newswire
Market Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on a High Note at 1.99 - The Dwinnex
Analysts Set Actinium Pharmaceuticals, Inc. (NYSE:ATNM) PT at $11.43 - MarketBeat
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Rating Increased to Hold at StockNews.com - MarketBeat
Quarterly Snapshot: Quick and Current Ratios for Actinium Pharmaceuticals Inc (ATNM) - The Dwinnex
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today! - AccessWire
Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to “Sell” at StockNews.com - Defense World
StockNews.com Downgrades Actinium Pharmaceuticals (NYSE:ATNM) to Sell - MarketBeat
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today! - AccessWire
Taking on analysts’ expectations and winning: Actinium Pharmaceuticals Inc (ATNM) - SETE News
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: - GlobeNewswire
ATNM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - AccessWire
Did Actinium Pharmaceuticals Inc (ATNM) perform well in the last session? - US Post News
ATNM’s Stochastic Averages Dip: Analyzing Actinium Pharmaceuticals Inc’s Stock Performance - The InvestChronicle
Closing Strong: Actinium Pharmaceuticals Inc (ATNM) Ends at 1.82, Down -6.67 from Last Close - The Dwinnex
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - AccessWire
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):